HLA-C and neoplasm: Essentially, ICB therapy still relies on the patient’s own immune system—in which major histocompatibility complex (MHC) proteins present peptides to T cells and activate a specific immune response—to kill tumor cells [6,7]; therefore, it is minimally toxic to normal cells and greatly improves prognosis, as evidenced by clinical trials [8,9].